PMID- 30913932
OWN - NLM
STAT- MEDLINE
DCOM- 20200528
LR  - 20200528
IS  - 1744-8417 (Electronic)
IS  - 1744-6651 (Linking)
VI  - 14
IP  - 3
DP  - 2019 May
TI  - Clinical management of difficult to treat macroprolactinomas.
PG  - 179-192
LID - 10.1080/17446651.2019.1596024 [doi]
AB  - INTRODUCTION: Prolactinomas represent the most common pituitary adenomas 
      encountered in the clinic. While a majority of these tumors will be successfully 
      treated by dopamine agonist (DA) such as cabergoline, their management becomes 
      problematic since a resistance to DA can occur and/or if the tumor displays 
      features of aggressiveness, two conditions that are closely related. AREAS 
      COVERED: Epidemiology and medical treatment of prolactinomas; resistance to DA 
      and molecular basis of DA-resistance; therapeutical alternatives in case of 
      DA-resistant Prolactinomas and therapies in development; summarizing conclusions. 
      EXPERT OPINION: The management of DA-resistant prolactinomas requires a 
      multidisciplinary approach by an expert team. Along with discussions about 
      surgery with or without gamma knife radiosurgery, genetic screening for multiple 
      endocrine neoplasia type 1 (MEN1) syndrome is actively discussed in a 
      case-by-case approach. In case of surgery, a careful analysis of the tumor sample 
      can provide information about its aggressivity potential according to recent 
      criteria. Ultimately, temozolomide can be indicated if the tumor is rapidly 
      growing and/or threatening for the patient.
FAU - Sahakian, Nicolas
AU  - Sahakian N
AD  - a Marseille Medical Genetics, Inserm U1251, Hopital de la Conception, Service 
      d'Endocrinologie , Aix Marseille Univ, APHM , Marseille , France.
FAU - Castinetti, Frederic
AU  - Castinetti F
AD  - a Marseille Medical Genetics, Inserm U1251, Hopital de la Conception, Service 
      d'Endocrinologie , Aix Marseille Univ, APHM , Marseille , France.
FAU - Dufour, Henry
AU  - Dufour H
AD  - b Marseille Medical Genetics, Inserm U1251, Hopital de la Timone, Service de 
      Neurochirurgie , Aix Marseille Univ, APHM , Marseille , France.
FAU - Graillon, Thomas
AU  - Graillon T
AD  - b Marseille Medical Genetics, Inserm U1251, Hopital de la Timone, Service de 
      Neurochirurgie , Aix Marseille Univ, APHM , Marseille , France.
FAU - Romanet, Pauline
AU  - Romanet P
AD  - c Marseille Medical Genetics, Inserm U1251, Hopital de la Conception, Laboratoire 
      de Biologie Moleculaire et Biochimie , Aix Marseille Univ, APHM , Marseille , 
      France.
FAU - Barlier, Anne
AU  - Barlier A
AD  - c Marseille Medical Genetics, Inserm U1251, Hopital de la Conception, Laboratoire 
      de Biologie Moleculaire et Biochimie , Aix Marseille Univ, APHM , Marseille , 
      France.
FAU - Brue, Thierry
AU  - Brue T
AD  - a Marseille Medical Genetics, Inserm U1251, Hopital de la Conception, Service 
      d'Endocrinologie , Aix Marseille Univ, APHM , Marseille , France.
FAU - Cuny, Thomas
AU  - Cuny T
AD  - a Marseille Medical Genetics, Inserm U1251, Hopital de la Conception, Service 
      d'Endocrinologie , Aix Marseille Univ, APHM , Marseille , France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190327
PL  - England
TA  - Expert Rev Endocrinol Metab
JT  - Expert review of endocrinology & metabolism
JID - 101278293
RN  - 0 (Dopamine Agonists)
SB  - IM
MH  - Disease Management
MH  - Dopamine Agonists/*therapeutic use
MH  - *Drug Resistance, Neoplasm
MH  - Humans
MH  - Pituitary Neoplasms/*drug therapy/metabolism
MH  - Prolactinoma/drug therapy/metabolism/*therapy
MH  - Signal Transduction/drug effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - PRLoma
OT  - dopamine agonist
OT  - radiosurgery
OT  - resistance
OT  - surgery
OT  - temozolomide
EDAT- 2019/03/28 06:00
MHDA- 2020/05/29 06:00
CRDT- 2019/03/28 06:00
PHST- 2019/03/28 06:00 [pubmed]
PHST- 2020/05/29 06:00 [medline]
PHST- 2019/03/28 06:00 [entrez]
AID - 10.1080/17446651.2019.1596024 [doi]
PST - ppublish
SO  - Expert Rev Endocrinol Metab. 2019 May;14(3):179-192. doi: 
      10.1080/17446651.2019.1596024. Epub 2019 Mar 27.